Abstracts Archive - Page 2328 of 2425 - ACR Meeting Abstracts

Abstract Number: 1400 • 2012 ACR/ARHP Annual Meeting
Predictors of Obesity in Systemic Lupus Erythematosus
Michelle Petri¹, Sesha Adusumilli² and Hong Fang¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Hypertension and obesity are the two most important traditional cardiovascular risk factors in the prediction of subclinical measures of atherosclerosis in SLE. Obesity is…
Abstract Number: 1401 • 2012 ACR/ARHP Annual Meeting
Characterization of Clinical Photosensitivity in Cutaneous Lupus Erythematosus
Kristen Foering¹, Aileen Y. Chang², Evan W. Piette², Joyce Okawa³ and Victoria P. Werth⁴, ¹Dermatology, University of Pennsylvania, Philadelphia VAMC, Philadelphia, PA, ²Dermatology/2nd Fl, University of Pennsylvania, Philadelphia, PA, ³Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania and Philadelphia V.A. Medical Center, Philadelphia, PA, ⁴Department of Dermatology, Veteran Affairs Medical Center, Philadelphia, PA
Background/Purpose: Photosensitivity (PS) is one of the most common manifestations of systemic lupus erythematosus (SLE), and is 1 of only 11 criteria used to make…
Abstract Number: 1402 • 2012 ACR/ARHP Annual Meeting
Anti-ApoA1 Antibodies Associate with Disease Activity in Lupus and Are Lower in Patients Taking Hydroxychloroquine: A Longitudinal Analysis of 398 Samples
Sara Croca¹, Ian Giles², David A. Isenberg³, Yiannis Ioannou⁴ and Anisur Rahman², ¹Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom, ²Centre for Rheumatology Research,Rayne Institute, 4th Floor, University College London, London, United Kingdom, ³Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ⁴Arthritis Research UK Centre for Adolescent Rheumatology at University College London, Great Ormond Street Hospital and UCLH, University College London, London, United Kingdom
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have a significantly increased risk of developing cardiovascular disease. The presence of chronic inflammation which characterizes SLE…
Abstract Number: 1403 • 2012 ACR/ARHP Annual Meeting
Anti-Nucleosome Antibodies Are Associated with Disease Activity and Hydroxychloroquine Use in Patients with Lupus: A Longitudinal, Multivariate Analysis of 398 Samples
Sara Croca¹, Ian Giles², David A. Isenberg³, Yiannis Ioannou⁴ and Anisur Rahman², ¹Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom, ²Centre for Rheumatology Research,Rayne Institute, 4th Floor, University College London, London, United Kingdom, ³Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ⁴Arthritis Research UK Centre for Adolescent Rheumatology at University College London, Great Ormond Street Hospital and UCLH, University College London, London, United Kingdom
Background/Purpose: Impaired apoptotic clearance appears to play a pivotal role in the pathogenesis of SLE leading to the accumulation of nuclear debris, such as nucleosomes,…
Abstract Number: 1404 • 2012 ACR/ARHP Annual Meeting
There Is an Association Between Disease Activity and Risk of Thromboembolism in SLE
Reem Jan¹, Emily E. Lewis², Ting Ting Lu¹, Emily Siegwald¹ and W. Joseph McCune³, ¹Rheumatology, University of Michigan, Ann Arbor, MI, ²Internal Medicine/Rheumatology, University of Michigan, Ann Arbor, MI, ³Int Med/ Rheum, University of Michigan, Ann Arbor, MI
Background/Purpose: Venous thromboembolism is a recognized complication of systemic lupus erythematosus (SLE). The role of antiphospholipid antibodies (aPL) in thrombogenesis is well documented; much less…
Abstract Number: 1405 • 2012 ACR/ARHP Annual Meeting
Real World Experience Comparing Multiplex Immunobead Assay versus Immunoflorescence Assay for Anti-Nuclear Antibody Detection At a University Hospital
Neha Dang¹, Brock E. Harper², Emilio B. Gonzalez¹, Silvia S. Pierangeli¹, Trisha M. Parekh³, Michael J. Loeffelholz⁴ and Kimberly K. Bufton⁵, ¹Rheumatology/Dept Int Med, University of Texas Medical Branch, Galveston, TX, ²Int Med/Rheumatology, University of Texas Medical Branch, Galveston, TX, ³Internal Medicine, University of Texas Medical Branch, Galveston, TX, ⁴Pathology, University of Texas Medical Branch, Galveston, TX, ⁵Microbiology, University of Texas Medical Branch, Galveston, TX
Background/Purpose: Anti-nuclear antibody (ANA) is considered a screening method for diagnosis of autoimmune disorders. Immunoflorescence ANA assay (IF) remains the gold standard for detection of…
Abstract Number: 1406 • 2012 ACR/ARHP Annual Meeting
The Cost of Management of Adult Active Systemic Lupus Erythematosus in the UK
Munther A. Khamashta¹, Christina Donatti², Ian N. Bruce³, Caroline Gordon⁴, David A. Isenberg⁵ and Ateka-Barrutia Oier⁶, ¹Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom, ²Health Economics and Outcomes Research, IMS Health, United Kingdom, ³Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit and NIHR Manchester Musculoskeletal Biomedical Research Unit, The University of Manchester, Manchester, United Kingdom, ⁴Rheumatology Research Group (East Wing), School of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom, ⁵Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ⁶Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom
Background/Purpose: Several international studies have shown that systemic lupus erythematosus (SLE) has a considerable financial burden on patients and the health-care economy. Little recent information…
Abstract Number: 1407 • 2012 ACR/ARHP Annual Meeting
The Effect of the Antiphospholipid Syndrome (APS) On Survival in Chinese Patients with SLE: A Prospective Study of 679 Patients
Chi Chiu Mok, Ling Yin Ho, Ka Lung Yu and Chi Hung To, Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong
Background/Purpose: To study the effect of the antiphospholipid syndrome (APS) on survival in Chinese patients with SLE Methods: A cohort of 679 southern Chinese patients…
Abstract Number: 1408 • 2012 ACR/ARHP Annual Meeting
Monitoring Patients with Systemic Lupus Erythematosus in Clinical Practice: Have You Already Checked the Vaccination Status in Your Patients?
Olga Malysheva, Jean-Philipp Ivanov, Sybille Arnold and Christoph G. Baerwald, Rheumatology, University Hospital, Leipzig, Germany
Background/Purpose: : Infection is one of the main causes of morbidity and increased mortality in patients with systemic lupus erythematodes (SLE). Information about vaccination history and…
Abstract Number: 1409 • 2012 ACR/ARHP Annual Meeting
A Multicentre Clinical Study of Umbilical Cord Mesenchymal Stem Cells Transplantation in Active Systemic Lupus Erythematosus
Lingyun Sun¹, Dandan Wang¹, Jing Li², Miao Zhang³, Yu Zhang⁴ and Xia Li¹, ¹Department of Rheumatology and Immunology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, ²Department of Rheumatology, Affiliated Hospital of Jiangsu University, Zhenjiang, China, ³Department of Rheumatology, Jiangsu Provincial People's Hospital, Nanjing, China, ⁴Department of Rheumatology, Subei People's Hospital of Jiangsu Province, Yangzhou, China
Background/Purpose: Umbilical cord (UC) derived mesenchymal stem cells (MSCs) have shown safety profile and therapeutic effect in severe and refractory systemic lupus erythematosus (SLE) in…
Abstract Number: 1410 • 2012 ACR/ARHP Annual Meeting
Relationship Between Individual Organ Damage and Mortality of Systemic Lupus Erythematosus (SLE): A Prospective Cohort Study of 679 Patients
Chi Chiu Mok, Ling Yin Ho and Ka Lung Yu, Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong
Background/Purpose: To study the relationship between damage in different organ systems and mortality in patients with SLE. Methods: 679 patients who fulfilled at least 4…
Abstract Number: 1411 • 2012 ACR/ARHP Annual Meeting
Equivalence of Various Language Versions of Lupus Specific Patient Reported Outcomes Measure (LupusPRO)
Meenakshi Jolly¹, Mark Kosinski², Sergio M.A. Toloza³, Joel A. Block⁴, Rachel A. Mikolaitis⁴, Sergio Durán-Barragan⁵, Ana M. Bertoli⁶, Ivana Blazevic⁷, Luis M. Vila⁸, Dilrukshie Cooray⁹, Emmanuel P. Katsaros¹⁰, Karina Marianne D. Torralba¹¹, Ioana Moldovan¹², Arif Kaya¹³, Berna Goker¹³, Seminur Haznedaroglu¹⁴, Mehmet E. Tezcan¹³, Josiane Bourré-Tessier¹⁵, Sasha Bernatsky¹⁶, Ann E. Clarke¹⁷, Michael H. Weisman¹⁸, Sandra V. Navarra¹⁹, Daniel J. Wallace²⁰ and Graciela S. Alarcon²¹, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²QualityMetric Inc, Lincoln, RI, ³Medicine, Hospital San Juan Bautista, Catamarca, Argentina, ⁴Section of Rheumatology, Rush University Medical Center, Chicago, IL, ⁵Unidad de Investigacion en Enfermedades Cronico-Degenerativas, Guadalajara, Mexico, ⁶Instituto Reumatológico Strusberg, Cordoba, Cordoba, Argentina, ⁷University of Buenos Aires, Buenos Aries, Argentina, ⁸Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, PR, ⁹Rheumatology, Harbor UCLA Medical Center, Torrance, CA, ¹⁰Int Medicine, Loma Linda Univ, Loma Linda, CA, ¹¹Rheumatology/Int Med, USC Keck Schl of Medicine, Los Angeles, CA, ¹²Loma Linda Univ Medical Center, Loma Linda, CA, ¹³Internal Medicine-Rheumatology, Gazi University Medical School, Ankara, Turkey, ¹⁴Internal Medicine-Rheumatology, Gazi University School of Medicine, Ankara, Turkey, ¹⁵Rheumatology, McGill University, Montréal, QC, Canada, ¹⁶Clinical Epidemiology, Research Institute of the McGill University Health Ctre, Montreal, QC, Canada, ¹⁷Division of Rheumatology, University of Calgary, Alberta, Calgary, AB, Canada, ¹⁸Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁹University of Santo Tomas Hospital, Manila, Philippines, ²⁰Cedars-Sinai Medical Center, Los Angeles, CA, ²¹Medicine, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Due to observed disparities in health outcomes in Systemic Lupus Erythematosus (SLE) across racial/ethnic groups, socioeconomic status, or health care systems, studies on group…
Abstract Number: 1412 • 2012 ACR/ARHP Annual Meeting
Vascular Cell Adhesion Molecule (VCAM-1) and Angiostatin in Systemic Lupus Erythematosus
Adnan Kiani¹, Hong Fang¹, Tianfu Wu², Chandra Mohan³ and Michelle Petri¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Division of Rheumatology/Internal Medicine, University of Texas, Southwestern Medical Center at Dallas, Dallas, TX, ³Internal Medicine/Division of Rheumatology, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Vascular cell adhesion molecule-1 (VCAM-1), an adhesion molecule, is involved in the progression of glomerular and tubulointerstitial injury. High levels of VCAM-1 have been…
Abstract Number: 1413 • 2012 ACR/ARHP Annual Meeting
Clinical Presentation, Treatment and Outcome of Membranous Nephropathy in SLE: A Comparison with Proliferative Lupus Glomerulonephritis in 141 Patients
Chi Chiu Mok, Ling Yin Ho and Ka Lung Yu, Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong
Background/Purpose: To study the presentation and outcome of membranous nephropathy in SLE in comparison with proliferative lupus glomerulonephritis. Methods: Patients with biopsy firmed active lupus nephritis…
Abstract Number: 1414 • 2012 ACR/ARHP Annual Meeting
Combination of Mycophenolate Mofetil and Tacrolimus for Refractory Lupus Nephritis: A 12-Month Open-Labeled Trial
Chi Chiu Mok, Pak To Chan, Ling Yin Ho and Ka Lung Yu, Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong
Background/Purpose: To evaluate the efficacy and tolerability of a combination of mycophenolate mofetil (MMF) and tacrolimus (Tac) for refractory lupus nephritis Methods: Patients with refractory…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].